Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials*
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The use of antifungal prophylaxis remains controversial in most populations including surgical intensive care unit patients. A meta-analysis of randomized controlled trials was performed to evaluate the safety and effectiveness of azoles as antifungal prophylaxis in high-risk patients receiving treatment in the surgical intensive care unit. DATA SOURCE: Data were obtained from PubMed, Current Contents, Cochrane central register of controlled trials, and references from relevant articles. STUDY SELECTION: Randomized controlled trials using azoles as antifungal prophylaxis vs. placebo were included in the study. DATA EXTRACTION: Two independent reviewers extracted data concerning the development of fungal infections (superficial or invasive), adverse effects, and mortality. SYNTHESIS: Six randomized controlled trials were included in the main analysis. Publication bias and statistically significant heterogeneity were not observed among the analyzed studies. Patients receiving antifungal prophylaxis developed fewer episodes of candidemia (odds ratio [OR] = 0.28, 95% confidence interval [CI] 0.09-0.86), nonbloodstream invasive fungal infections (OR = 0.26, 95% CI 0.12-0.53), and noninvasive (superficial) fungal infections (OR = 0.22, 95% CI 0.11-0.43), respectively. No reduction in mortality was observed among patients who received azole prophylaxis (OR = 0.74, 95% CI 0.52-1.05). There was no significant difference in reported adverse effects (OR = 1.28, 95% CI 0.82-1.98). CONCLUSIONS: Despite its limitations, our meta-analysis suggests that the prophylactic use of azoles in high-risk surgical intensive care unit patients is associated with a reduction of fungal infections but not in all-cause mortality. However, although not noted in the analyzed randomized controlled trials, there is concern about the use of azoles due to possible shift toward non-albicans species and development of resistance to azoles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., & Saral, R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199110313251803 · Cited by 937
Viscoli, C., Girmenia, C., Marinus, A., Collette, L., Martino, P., Vandercam, B., Doyen, C., Lebeau, B., Spence, D., Krcmery, V., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/514731 · Cited by 601
Importance of Candida Species Other than C. albicans as Pathogens in Oncology Patients
Wingard, J. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.1.115 · Cited by 542 · cited 1×
“glabrata exhibit innate resistance to fluconazole, the azole most widely used for antifungal prophylaxis, supports the previous findings (61, 64, 65).”
ResultFluconazole prophylaxis against fungal colonization and infection in preterm infants.
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., & Donowitz, L. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010494 · Cited by 523
Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients
Eggimann, P., Francioli, P., Bille, J., Schneider, R., Wu, M.-M., Chapuis, G., Chiolero, R., Pannatier, A., Schilling, J., Geroulanos, S., et al. (1999) · Critical Care Medicine · doi:10.1097/00003246-199906000-00019 · Cited by 414
Winston, D. J., Pakrasi, A., & Busuttil, R. W. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-10-199911160-00003 · Cited by 261
Sandven, P., Qvist, H., Skovlund, E., & Giercksky, K. E. (2002) · Critical Care Medicine · doi:10.1097/00003246-200203000-00008 · Cited by 201
Cited by
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Cornely, O. A., Bassetti, M., Calandra, T., Garbino, J., Kullberg, B. J., Lortholary, O., Meersseman, W., Akova, M., Arendrup, M. C., Arikan-Akdagli, S., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12039 · Cited by 1,217
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
León, C., Ruiz-Santana, S., Saavedra, P., Galván, B., Blanco, A., Castro, C., Balasini, C., Utande-Vázquez, A., González de Molina, F. J., Blasco-Navalproto, M. A., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819daa14 · Cited by 375
Metadata
- Authors
- Vardakas, K. Z., Samonis, G., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E.
- Venue
- Critical Care Medicine
- Published
- 2006-04
- Volume
- 34
- Issue
- 4
- Pages
- 1216-1224
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2076924803
- Cited by
- 91
- References
- 7
- FWCI
- 1.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials*. https://app.cochat.ai/papers/10.1097/01.ccm.0000208357.05675.c3
- The paper
- Vardakas, K. Z., Samonis, G., Michalopoulos, A., Soteriades, E. S., & Falagas, M. E. (2006). Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials*. Critical Care Medicine. https://doi.org/10.1097/01.ccm.0000208357.05675.c3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.